This website is intended for healthcare professionals only

Trending Topic

Comprehensive Anatomical Render Of Breast Cancer In A Human Female
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]

Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers

6 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2022

The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into how the mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers.

The abstract entitled ‘Mechanism of action and an actionable inflammatory axis for air pollution induced non-small cell lung cancer: Towards molecular cancer prevention‘ Abstract 659MO, was presented at European Society for Medical Oncology (ESMO) 2022.

Questions:

  1. What is known about the cause of non-small cell lung cancer (NSCLC) in never smokers? (0:18)
  2. What were the aims, methodology and findings of your study? (1:00)
  3. What opportunities has this study presented for therapeutic development? (5:05)

Disclosures: Charles Swanton has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of ESMO 2022

Access more lung cancer content here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup